With a CD8-targeting IL-2 mutein as its lead program, the start-up is developing cis-targeted immunotherapies that selectively target two molecules on the same immune cell for improved efficacy and safety.

Semorinemab met only the cognition co-primary endpoint in the Phase II LAURIET trial in mild-to-moderate Alzheimer’s patients and missed all secondary endpoints, but some firsts were achieved in the top-line readout.

Panel discussion illustrated how decentralized approaches can expand the possibilities of studies in rare diseases, such as cancers with rare genomic alterations.

Interview: The Swiss biotech has endured many Alzheimer’s failures, but has been able to broaden its portfolio and income streams while the search for a breakthrough goes on.